Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496764 | 0.88 | PDE2A (0.44) | PDE2AKAT2BHSD11B1EPHX2 | |
| SCHEMBL2823870 | 0.88 | PDE2A (0.46) | PDE2AKAT2BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL496651 | 0.86 | PDE2A (0.46) | PDE2AKAT2BHSD11B1EPHX2MEN1 | |
| SCHEMBL496524 | 0.85 | PDE2A (0.53) | PDE2AKAT2BMEN1KMT2ATP53 | |
| SCHEMBL496849 | 0.83 | PDE2A (0.56) | PDE2AKAT2BTP53MAPTHPGD | |
| SCHEMBL2824766 | 0.81 | POLB (0.41) | PDE2AKAT2BMEN1KMT2AKDM4E | |
| SCHEMBL496930 | 0.80 | PDE2A (0.51) | PDE2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL496714 | 0.80 | PDE2A (0.51) | PDE2AKAT2BTP53MAPTTSHR | |
| SCHEMBL496929 | 0.79 | ABCG2 (0.44) | PDE2AALDH1A1KMT2AKDM4E | |
| SCHEMBL496525 | 0.77 | CA9 (0.41) | PDE2AKAT2BHSD11B1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-7851472-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-1791543-B1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20090005372-A1 | Triazolophthalazines | ALTANA PHARMA AG (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1836207-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1791543-A2 | TRIAZOLOPHTHALAZINES | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006072615-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006024640-A2 | TRIAZOLOPHTHALAZINES | ALTANA PHARMA AG (DE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | PDE2A, PDE12, PDE3A | PDE2A 1/4885KAT2B 1046/4885HSD11B1 196/4885 |
| US-20090005372-A1 | Triazolophthalazines | PDE2A, PDE12, PDE3A | PDE2A 1/4885KAT2B 1046/4885HSD11B1 196/4885 |
| US-20080312225-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | PDE2A 1/4885KAT2B 1316/4885HSD11B1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.